Embrace Change Acquisition Corp - Rights Azioni (NASDAQ: EMCGR)

Ultime notizie per Embrace Change Acquisition Corp - Rights (NASDAQ:EMCGR) Azioni

Embrace Change Acquisition Corp - Rights

enCore Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EU#AMEX">EU</a>) reported quarterly losses of $(0.13) per share. This is a 225 percent decrease over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $18.24 million which beat the analyst consensus estimate of $15.10 million by 20.79 percent. This is a 39.99 percent decrease over sales of $30.39 million the same period last year.

Earnings

Earnings Beats

News

enCore Energy Q1 EPS $(0.13) Down From $(0.04) YoY, Sales $18.24M Beat $15.10M Estimate

Black Diamond Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.02 by 4800 percent. This is a 380 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $70.00 million which beat the analyst consensus estimate of $17.50 million by 300.00 percent.

BDTX

Black Diamond Therapeutic Q1 EPS $0.98 Beats $0.02 Estimate, Sales $70.00M

ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.40) by 82.5 percent. This is a 83.89 percent increase over losses of $(4.53) per share from the same period last year.

Earnings Misses

ZVSA

ZyVersa Therapeutics Q1 EPS $(0.73) Misses $(0.40) Estimate

Barrington Research analyst Alexander Paris maintains Lincoln Educational Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINC#NASDAQ">LINC</a>) with a Outperform and raises the price target from $22 to $25.

Price Target

Analyst Ratings

LINC

Barrington Research Maintains Outperform on Lincoln Educational Servs, Raises Price Target to $25

Plug Power Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) reported financial results for the first quarter after the market close on Monday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/05/g45358934/plug-reports-first-quarter-2025-financial-results">of the report</a>.
Q1 Earnings: Plug Power reported first-quarter revenue of $133.67 million, beating analyst&nbsp;<a href="http://benzinga.com/quote/plug/earnings" target="_blank" rel="noreferrer noopener">estimates</a>&nbsp;of $132.16 million. Total revenue was up from $120.26 million in the prior year&#8217;s quarter. 
The company reported a first-quarter loss of 21 cents per share, missing analyst estimates for a loss of 19 cents per share, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Plug said its results were driven by growing electrolyzer deliveries, continued demand in material handling and ongoing deployments in the company&#8217;s cryogenic platform. The company noted that GenEco electrolyzer sales increased&nbsp;575%&nbsp;on a year-over-year basis. 
Net cash used in operations and investing activities declined to $152.1 million in the quarter, down from $288.3 million in the first quarter of 2024. Plug ended the quarter with approximately $295.8 million&nbsp;in unrestricted cash.
&#8220;In 2025, we are focused on three core areas: material handling, electrolyzers and hydrogen supply. These are the businesses where Plug holds competitive advantages — and where we believe we can deliver the most meaningful impact for our customers and investors,&#8221; the company said in the earnings release.
Guidance:&nbsp;Plug Power expects second-quarter revenue to be in the range of $140 million to $180 million versus <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates of $132.16 million. 
Plug said it plans to focus on driving continued global adoption of its GenEco electrolyzer platform in 2025, while advancing financing initiatives such as investment tax credit transfers and project equity alignment to support long-term capital efficiency.
&#8220;With new capacity online in Louisiana, accelerating adoption of our GenEco electrolyzers, and improved cash flow discipline, Plug is executing with focus and urgency. We&#8217;re delivering real progress toward profitability and scaling our hydrogen ecosystem to meet growing global demand for clean energy,&#8221; said&nbsp;Andy Marsh, CEO of Plug Power.
Plug reported <a href="https://www.benzinga.com/news/earnings/25/04/45038400/plug-power-rallies-as-new-financing-cost-cuts-boost-confidence-in-turnaround-plan">preliminary results</a> for the first quarter at the end of April, which may help explain some of Monday&#8217;s muted reaction. 
Plug&#8217;s management team will hold a conference call at 4:30 p.m. ET to further discuss the quarter with investors and analysts.
PLUG Price Action: <a href="http://benzinga.com/quote/PLUG">Plug Power shares</a> were down 3.73% after-hours, trading at 87 cents at the time of publication Monday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45353123/quantum-stocks-are-hot-in-2025-biggest-movers-to-watch">Quantum Stocks Are Hot In 2025: Biggest Movers To Watch</a></li>
</ul>
Photo: courtesy of Plug Power.

Guidance

After-Hours Center

Movers

PLUG

Plug Power Q1 Earnings: Revenue Beats Estimates Driven By 575% Growth In Electrolyzer Sales, EPS Falls Short, Company Highlights 'Real Progress' Toward Profitability

Hour Loop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOUR#NASDAQ">HOUR</a>) reported quarterly earnings of $0.02 per share. This is a 33.33 percent decrease over earnings of $0.03 per share from the same period last year. The company reported $25.84 million in sales this quarter. This is a 4.68 percent increase over sales of $24.68 million the same period last year.

HOUR

Hour Loop Q1 EPS $0.02 Down From $0.03 YoY, Sales $25.84M Up From $24.68M YoY

Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.13) by 7.69 percent. This is a 48.15 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $6.44 million which missed the analyst consensus estimate of $7.42 million by 13.21 percent. This is a 1.24K percent increase over sales of $481.00 thousand the same period last year.

SGMO

Sangamo Therapeutics Q1 GAAP EPS $(0.14) Misses $(0.13) Estimate, Sales $6.44M Miss $7.42M Estimate

WIIM

MVIS

MicroVision shares are trading lower after the company reported worse-than-expected Q1 financial results.

NRGV

Energy Vault Holdings shares are trading lower after the company reported worse-than-expected Q1 financial results.

Consolidated Water Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWCO#NASDAQ">CWCO</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.27 by 14.81 percent. This is a 27.91 percent decrease over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $33.72 million which beat the analyst consensus estimate of $32.30 million by 4.38 percent. This is a 15.05 percent decrease over sales of $39.69 million the same period last year.

CWCO

Consolidated Water Co Q1 EPS From Continuing Operations $0.31 Beats $0.27 Estimate, Sales $33.72M Beat $32.30M Estimate

Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) reported quarterly losses of $(0.82) per share which beat the analyst consensus estimate of $(0.85) by 3.53 percent. This is a 51.85 percent decrease over losses of $(0.54) per share from the same period last year. The company reported quarterly sales of $1.16 million which beat the analyst consensus estimate of $804.30 thousand by 44.60 percent. This is a 33.07 percent increase over sales of $874.00 thousand the same period last year.

DNTH

Dianthus Therapeutics Q1 EPS $(0.82) Beats $(0.85) Estimate, Sales $1.16M Beat $804.30K Estimate

VTSI

VirTra shares are trading higher after the company reported better-than-expected Q1 financial results.

Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) reported quarterly losses of $(0.82) per share which beat the analyst consensus estimate of $(0.85) by 3.53 percent. This is a 51.85 percent decrease over losses of $(0.54) per share from the same period last year.

Dianthus Therapeutics Q1 EPS $(0.82) Beats $(0.85) Estimate

Electro-Sensors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELSE#NASDAQ">ELSE</a>) reported quarterly losses of $(0.02) per share. The company reported $2.24 million in sales this quarter. This is a 0.22 percent decrease over sales of $2.24 million the same period last year.

ELSE

Electro-Sensors Q1 EPS $(0.02), Sales $2.24M Down From $2.24M YoY

Babcock &amp; Wilcox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.13) by 100 percent. This is a 13.04 percent decrease over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $181.20 million which beat the analyst consensus estimate of $162.60 million by 11.44 percent. This is a 12.72 percent decrease over sales of $207.60 million the same period last year.

Babcock & Wilcox Q1 EPS $(0.26) Misses $(0.13) Estimate, Sales $181.20M Beat $162.60M Estimate

Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.59) by 55.93 percent. This is a 21.05 percent decrease over losses of $(0.76) per share from the same period last year. The company reported quarterly sales of $4.66 million which beat the analyst consensus estimate of $706.00 thousand by 559.77 percent. This is a 310.40 percent increase over sales of $1.14 million the same period last year.

EDIT

Editas Medicine Q1 EPS $(0.92) Misses $(0.59) Estimate, Sales $4.66M Beat $706.00K Estimate

<a href="https://www.globenewswire.com/Tracker?data=AgroyJiAoVwZWpbl3I_g5vXwkNryrBhcKWKtKMfwr5SJGrEArF-F94LVj29UByPwOitbzBikvRMaG94-AUB-kjWcMKBb10qs8XHJ_NGO85I=">Beam Therapeutics Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing mutation in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited genetic disorder that affects the lungs and/or liver, leading to early onset emphysema and liver disease, and for which there is significant unmet need for effective therapies that can treat the entire spectrum of disease.
"Just weeks after the clearance of our U.S. investigational new drug application, we are pleased to report that the FDA has now granted RMAT designation to BEAM-302, recognizing its potential as a transformative, one-time treatment for patients living with AATD," said Giuseppe Ciaramella, Ph.D., president of Beam Therapeutics. "This designation underscores the strength of our clinical data to date and the promise of base editing to directly correct the genetic mutation that is the root cause of most cases of severe AATD. With RMAT designation enabling closer and more frequent collaboration, we look forward to working with the FDA to accelerate the development of BEAM-302 and bring this potentially curative therapy to AATD patients as safely and swiftly as possible."
The FDA's RMAT designation is designed to support the development and evaluation of regenerative medicines, including genetic therapies, with the intention of addressing serious or life-threatening diseases that have unmet medical needs. RMAT designation provides opportunities for early interactions with the FDA to discuss potential surrogate or intermediate endpoints to support accelerated approval, organizational commitment from senior staff at the agency, opportunities to participate in novel review and development programs, and the potential for a rolling review and priority review of a product's future biologics license application.
Positive initial safety and efficacy data from the Phase 1/2 trial of BEAM-302 were previously <a href="https://www.globenewswire.com/Tracker?data=DA7vCfMfeWFXeIxzmWuCQbq57-hOQDq3lYcM01eYzAB2DDZYKNsjZwr_iq5_TDmR93QBOR24G6ICtFMNBz4iR0AAgLewn-IQvVD3cuv0TM1xUJyrh4OIAmqse6MMY42kX6v-_EFDrgneDyjxRqX56dJMQ7rYyGNbYI9Q0FsN60LtxsUV4SKfM6WCVgfyqPQg1icVyi4ZHOANTZ4Tk3sS5w6sgMl7aBvX-wWLvbIdaeg=">reported</a> in March, establishing clinical proof of concept as a potential treatment for AATD and in vivo base editing. Preliminary results from the first three single-ascending dose cohorts in Part A of the study demonstrated that BEAM-302 was well tolerated, with single doses of BEAM-302 leading to durable, dose-dependent correction of the disease-causing mutation and total AAT protein levels above the therapeutic threshold in the 60 mg dose cohort. Beam has initiated dosing in the fourth cohort of Part A, evaluating 75 mg of BEAM-302, and expects to report updated data at a medical conference in the second half of 2025. Additionally, the company plans to dose the first patient in Part B, which will include AATD patients with mild to moderate liver disease, in the second half of 2025 as well. Beam previously <a href="https://www.globenewswire.com/Tracker?data=qIH9yhF1SSXMfkVvvTYJsHJzgR09c_h4Fzs6J2NhuVvsfsO-MFzw8sKbiBy1aKE9_hIU_LzaNZHs8IDLS6VKRt5dosCJbNgPC64GjaLtiLtUorZWh-uZOh0eY1lQscRRLzzsg_bQAYNSna04P_oxjXcmzQVsk-bNbg9W444LLcc3CfXmp7C9D-vR1A3in00XgQJd-oLO2tZPsad8TI3rigL5twRVo72RY3aPtfB7H0o=">announced</a> the clearance of the U.S. investigational new drug (IND) application for BEAM-302 for the treatment of AATD in March 2025. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
About BEAM-302 BEAM-302 is a liver-targeting lipid-nanoparticle (LNP) formulation of base editing reagents designed to correct the PiZ mutation. Patients homozygous for this mutation (PiZZ) represent the majority of patients living with severe AATD disease. A one-time A-to-G correction of the PiZ mutation with Beam's adenine base editor has the potential to simultaneously reduce the aggregation of mutant, misfolded AAT protein that causes toxicity to the liver (Z-AAT), generate therapeutic levels of corrected protein (M-AAT), and increase total and functional AAT in circulation, thereby addressing the underlying pathophysiology of both the liver and lung disease. In addition, the reduction in circulating PiZ aggregates (i.e., polymers) has the potential to further minimize lung inflammation and dysfunction. Importantly, because the native AAT gene would be corrected in its normal genetic location, AAT levels are anticipated to increase physiologically in response to inflammation or infection. This is a critical aspect of AAT's normal function to regulate the body's inflammatory response, which does not occur with currently approved protein replacement therapies. Correction of the PiZ mutation is expected to be durable based on preclinical and clinical evidence.

Biotech

General

BEAM

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy Designation Has Been Granted To BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency

Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.31) by 19.35 percent. This is a 4.17 percent decrease over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $342.00 thousand which beat the analyst consensus estimate of $144.30 thousand by 137.01 percent. This is a 5.23 percent increase over sales of $325.00 thousand the same period last year.

CATX

Perspective Therapeutics Q1 EPS $(0.25) Beats $(0.31) Estimate, Sales $342.00K Beat $144.30K Estimate

Fuel Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEK#NASDAQ">FTEK</a>) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is a 300 percent decrease over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $6.38 million which missed the analyst consensus estimate of $6.64 million by 3.89 percent. This is a 28.75 percent increase over sales of $4.96 million the same period last year.

FTEK

Fuel Tech Q1 EPS $(0.02), Inline, Sales $6.38M Miss $6.64M Estimate

OPRX

OptimizeRx shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sale guidance with its midpoint above estimates.

Comments

Embrace Change Acquisition Corp - Rights

Notizie

Ultime notizie per Embrace Change Acquisition Corp - Rights (NASDAQ:EMCGR) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO